Entegris (ENTG) rated SELL after a 50% YTD rally: 40x FY2026 P/E, limited AI exposure, debt overhang, and weak catalysts—read ...
Company to engage industry partners and distribution channels as part of expanding BioCosmeceutical commercialization strategyMELVILLE, N.Y., ...
Stevanato Group (NYSE:STVN) executives said the company closed fiscal 2025 with “solid” results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diagn ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results